Not approved, not even tested with an appropriate clinical trial, but research has again shown that the use of statins in men with prostate cancer may have a lower risk of dying from the cancer than those who do not. In a study of 1,001 prostate cancer patients who were diagnosed between 2002 and 2005, [...]
In 1999 there was a new company started, InSightec, when GE Healthcare and Elbit Medical imaging joined their technologies to develop and manufacture non-invasive magnetic resonance (MRI) guided focused ultrasound technologies. The company has been in the process of developing a system that combines MRIs with ultrasound to non-surgically destroy fibroids and tumors. The company [...]
Currently as our advanced prostate cancer progresses and we develop bone and soft tissue tumors our pain increases significantly. Current treatment options for the palliation of this pain includes painkillers (including opioids and methadone), radiation and in rare incidents surgery. All of these options have significant limitations. Drugs eventually become less effective, especially for breakout [...]
GTx Inc. had a poster honored as one of the best posters at the 28th Annual European Association of Urology Congress held in Milan Italy March 15 2013. The poster presentation which had the very long title of “GTx-758 an ERa Agonist Reduces Serum Free Testosterone Lower than can be Achieved by Leuprolide with a [...]
There was a recent interview in the Pharma Strategy Blog with Dr. Bertrand Tombal , an academic urologist in Belgium. Dr. Tomal discussed several of the new advances in the treatment od advanced prostate cancer with an emphasis on the potential future of Enzalutamide (Xtandi). Like bicalutamide (Casodex), Xtandi works by blocking (inhibiting) testosterone from [...]